AIDS Deals Heat Up--In Both Private and Public Sectors
Executive Summary
Abbott Laboratories' Norvir (ritonavir) set a record early in March: the FDA reviewed and approved the protease inhibitor for use alone or in combination therapy as a treatment for late-stage AIDS just 72 days after filing.
You may also be interested in...
Clinical Update: AIDS Research Marches On
A short discussion of the state of HIV/AIDS research, including drug and vaccine development, reversing AIDS' destructive process, and new studies in this area.
Japan Grants Global-First Approval To Zolbetuximab, 15 Other New Drugs
Astellas's first-in class CLDN18.2-targeting antibody receives its first approval worldwide, while crovalimab and a number of drugs for rare diseases also receive nods from regulators and are now awaiting reimbursement price-listing.
Hanmi-OCI Merger Hits Wall As Brothers Win Shareholder Vote, Board Seats
The planned merger of Korea's Hanmi Pharm Group with OCI Group hits a major speed bump as the two sons of Hanmi's founder and other candidates recommended by them secture board seats. But it remains to be seen how the Lim brothers will fulfil their ambitious promises.